April 2018
Dear UAEMers all over Europe!
We are pleased to share with you our latest news from UAEM Europe. Email us at uaemeuropenewsletter@gmail.com for any content you'd like to see in the May issue.
Enjoy reading,
The Newsletter team -- Marie, David (Germany) and Rosie (Ireland)
|
|
|
|
Happy Easter from all of us at UAEM Europe!
|
|
UAEM Europe Conference 2018 in Maastricht
As the winter is leaving us, Maastricht is coming, and we hope you are too.
It takes place on April 20th-22nd and it will focus on the theme of transparency, in line with our global campaign.
Guest speakers and experts working on relevant issues will be invited to provide insights on different aspects of the access to medicines movement. Among the speakers are Gaëlle Krikorian, an advisor on Acces to Knowledge and Intellectual Property for the Greens at the European Parliament and Martin Harvey, the International Affairs Officer for the European Medicine's Agency.
For fiurther information on the conference you can contact the organizing commitee through heir website.
With nearly 150 people having registered, the conference will be running at full capacity.
To get you excited you should watch their newest teaser unless you haven't seen the first one.
We hope to see you soon in Maastricht!
|
|
Reducing pharmaceutical pollution to tackle AMR
January 30th: The European Public Health Allicance (EPHA) organised an event at the European Parliament, together with Changing Markets Foundation and the European Environmental Bureau, to discuss synergies between the available policy measures for tackling pharmaceuticals in the environment (PiE) and antimicrobial resistance (AMR). The event was hosted by MEP Annie Schreijer-Pierik (EPP, Netherlands) who emphasised the importance of assuming responsibility and taking a multi-stakeholder approach to minimise the negative consequences of pollution in Europe and globally.
Read more here: https://epha.org/no-more-silo-thinking-reducing-pharmaceuticals-in-the-environment-and-amr/?platform=hootsuite
|
|
|
|
Neglected Tropical Disease of the Month
Each month we will showcase a new NTD to raise awareness!
10 facts about Leprosy
- Mycobacterium leprae is a bacteria found globally, most affecting India and Sub-Saharan Africa
- Found in: humans and wild armadillos in the USA
- Flourishes in: mouth and nose
- Acquired by: droplets
- Causes: nerve damage, muscle weakness, blindness
- Treatment: WHO recommends a combination of rifampicin, clofazimine and dapsone
- How does this relate to access to medicines? In 2016 WHO launched the Global Leprosy Strategy 2016–2020: Accelerating towards a leprosy-free world. Also, rifampicin resistance is becoming more prevalent, which causes struggles in areas where a MDT is difficult to access.
- Read more here.
|
|
Do you know how access to medicines is monitored for the SDGs?
Sustainable Development Goal 3, Good health and Wellbeing, has a number of tracer indicators that have been created in order to monitor it's progression every 2 years around the world. But how does the Interagency Expert Group on SDG indicators assure that A2M is adequetely being evaluated? There are currently 6 indicators that aim to cover A2M:
Target 3.3: By 2030, end the epidemics of AIDS, TB, malaria and neglected tropical diseases (NTDs) and combat hepatitis, water-borne diseases and other communicable diseases.
-
Average annual number of people requiring preventive chemotherapy (PC) for at least one PC-NTD; plus
-
population at risk requiring mass treatment for yaws eradication; plus 3. number of new cases requiring individual treatment (disease management) for other NTDs.
Target 3.b.3 Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis
Target 3.8: Universal Health Coverage Tracer indicators:
- Malaria Prevention (% of population in endemic areas sleeping under bednets)
- HIV treatment (% of people requiring HIV treatment currently receiving HIV)
- Tuberculosis treatment (% of incidence of TB cases that are detected and successfuly treated in a given year)
You can read more here:
|
|
|
|
|
|
